SEPN

Septerna, Inc. Health Care Pharmaceutical Preparations Russell 3000

$44.00Close $2.0BMarket cap $18.10 – $48.1952-week range Nov 9, 2026Next report

Highlights

Strengths

In a stage-2 uptrend all 8 trend conditions pass
Leading the market RS 95 · stronger than 95% of stocks over 12 months

Cautions

Past its pivot 7.1% above its $41.09 pivot
Results soon Nov 9, 2026, in 8 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 10, 2026

Off 12-month high 9%

1wk 8.9% price change

1mo 12.4% price change

12-month return 105% market up 11% · its own up 90%

F-score — — Not assessed

Altman Z 5.48 Low risk

P/E — price / earnings

PEG — P/E / EPS growth

P/B 5.2× price / book

Earnings yield 3.7% EBIT / enterprise value

Cheaper than 40% of the market · expensive

Revenue growth 4175% year on year

EPS growth — latest quarter

Sales growth 22376% latest quarter · +10365 pts

ROE 12% return on equity

Free cash margin 239% $109.7M FCF

D/E — long-term debt / equity

Net debt / EBITDA —

Interest cover —EBIT / interest

Piotroski tests

Repair signals

FCF turned positive ($-70M → $110M)

Trade setup

ATR% 5.2% $2.30 a day · 2×ATR $39.39

RS 95 / 99 vs the universe

Trend 8 / 8 trend template

Relative volume 0.6× vs 50-day average

Up/down volume 1.01 50 sessions

Implied move — no option chain · report Nov 9, 2026

Contractions 2 30% → 16%

Pivot $41.09 7.1% above

Volume dry-up 0.8× 10 vs 50 sessions

Trend template · 8 of 8

Screen verdict

Did not qualify for any screen.

Warning signs

none flagged

No restatement or impairment
Equity positive
Interest covered
No material dilution
Profits tracking cash
Margins and revenue not shrinking

Last reported Aug 10, 2026

Results reaction Aug 10, 2026+24% vs market2 sessions after results

Financials

3 fiscal years · from filings

Revenue What customers paid the company over its fiscal year, before any cost, as filed in its annual report. The change is against the year before. Methodology $46.0M +4175% on FY2024

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$48.9M

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology $109.7M back to a profit

Margins Each as a share of revenue. Gross: left after the direct cost of what was sold. Net: left after every cost. Free cash: free cash flow over revenue. A margin rising over years means the business keeps more of each dollar it sells. Methodology

Net -106%
Free cash 239%

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 44.81m +1314.3% since FY2023

	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Revenue	$151,000	$1.1M	$46.0M
Operating income	$2.1M	-$80.8M	-$68.3M
Net income	$4.2M	-$71.8M	-$48.9M
Net margin	2768%	-6679%	-106%
Earnings per share	$1.92	-$7.26	-$1.10
Free cash flow	-$41.6M	-$69.6M	$109.7M
Free cash margin	-27550%	-6472%	239%
Cash	$88.5M	$238.2M	$120.7M
Shareholders' equity	-$38.4M	$420.0M	$381.9M
Shares outstanding	3.17m	44.42m	44.81m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 10, 2026	Quarterly ↗	Jun 30, 2026	41d
May 11, 2026	Quarterly ↗	Mar 31, 2026	41d
Mar 9, 2026	Annual ↗	Dec 31, 2025	68d
Nov 10, 2025	Quarterly ↗	Sep 30, 2025	41d
Aug 11, 2025	Quarterly ↗	Jun 30, 2025	42d
May 15, 2025	Quarterly ↗	Mar 31, 2025	45d
Mar 27, 2025	Annual ↗	Dec 31, 2024	86d
Nov 20, 2024	Quarterly ↗	Sep 30, 2024	51d

Current reports

Filed	Disclosed
Aug 25, 2026	Regulation FD · Other events ↗
Aug 10, 2026	Results ↗
Jun 30, 2026	Shareholder vote ↗
May 11, 2026	Results ↗
Apr 13, 2026	Regulation FD ↗
Mar 9, 2026	Results ↗
Mar 2, 2026	Regulation FD · Other events ↗
Jan 12, 2026	Regulation FD ↗
Jan 8, 2026	Regulation FD ↗
Nov 10, 2025	Results ↗
Sep 29, 2025	Director or officer change · Regulation FD ↗
Sep 3, 2025	Regulation FD ↗